Stay updated on Dato-DXd vs Chemo in Triple-negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Dato-DXd vs Chemo in Triple-negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dato-DXd vs Chemo in Triple-negative Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study details of a Phase III clinical trial comparing the efficacy and safety of Dato-DXd versus Investigator's Choice Chemotherapy in patients with locally recurrent inoperable or metastatic Triple-negative Breast Cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
    Difference
    0.0%
    Check dated 2024-06-06T14:42:08.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed eligibility criteria for participants, including age, health conditions, and prior treatments, replacing the previous placeholder text that indicated no information was provided.
    Difference
    39%
    Check dated 2024-05-22T21:00:40.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T21:58:48.000Z thumbnail image

Stay in the know with updates to Dato-DXd vs Chemo in Triple-negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dato-DXd vs Chemo in Triple-negative Breast Cancer Clinical Trial page.